Pharmaceutical Industry discussion, review, analysis, news and information.

Zelapar, a monoamine oxidase-B (MAO-B) inhibitor, is the first Parkinson's disease treatment to use a novel oral delivery system called Zydis® Technology, which allows the tablets to dissolve within seconds in the mouth and deliver more active drug at a lower dose.

"The unique formulation of Zelapar allows the orally disintegrating tablet to dissolve within seconds. By delivering more active drug at a lower dose, Zelapar significantly reduces "off" time, giving valuable hours back to the patient."